Flemming Ornskov, Shire

CEO, Shire
Total 2014 Compensation: $14.22 million

Shire ($SHPG) revenue skyrocketed by 23% in 2014, thanks to solid drug sales growth and a $4.2 billion deal for rare disease drugmaker ViroPharma, which closed in January. But CEO Flemming Ornskov might have scored even more growth had a hostile bid from AbbVie ($ABBV) not interfered with his M&A plans.

Ornskov and Shire ended up flying solo again, after new tax inversion rules prompted AbbVie to drop its pursuit--and pay a breakup fee of $1.635 billion. With $5.83 billion on its 2014 top line, the company is 60% of the way to its goal of $10 billion in sales by 2020. And with that breakup fee now in its war chest, it's back on the M&A trail, with two deals to its credit so far in 2015.

Meanwhile, Shire asked FDA to bless a new use for its ADHD drug Vyvanse in binge eating disorder--an app that's been approved since. Ornskov figures that could add $300 million to the drug's peak sales.

For all that activity, Ornskov collected $1.3 million in base salary, plus a $1.76 million cash bonus and short-term equity award of $585,000. His retirement benefits amounted to $390,000, and other benefits, $107,000. That put his total for his fixed and short-term pay at $4.14 million.

Shire also granted Ornskov some long-term share awards that won't vest till 2017; at 100% vesting, those would be worth $5.76 million and $4.32 million, respectively, bringing his total to $14.22 million.

For more:
Special Reports: Pharma's top 10 M&A deals of 2013 - Shire/ViroPharma | The 25 most influential people in biopharma today - 2013 - Flemming Ornskov
Shire could use boost from adult ADHD med to hit $10B goal
Shire's ADHD star Vyvanse scores FDA's first binge eating approval
Shire CEO extends deal drive with $5.2B NPS Pharma buyout
Shire CEO eyes $10B sales goal with more M&A deals in mind
Shire CEO happy to fly solo again after AbbVie deal's collapse

Flemming Ornskov, Shire
Read more on

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.